Cohen E A, Mulligan D, Kulkarni S, Tichy E M
Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT.
Department of Surgery, Yale University, New Haven, CT.
Am J Transplant. 2016 Sep;16(9):2753-7. doi: 10.1111/ajt.13852. Epub 2016 Jun 7.
Benefits of belatacept-based immunosuppressive regimens in human immunodeficiency virus (HIV)-positive renal transplant recipients include avoidance of drug interactions between calcineurin inhibitors and highly active antiretroviral agents and decreased likelihood or severity of nonimmune toxicities such as new-onset diabetes after transplant, hyperlipidemia and hypertension. We report a successful case of de novo belatacept at >18 mo from transplant in an HIV-positive black man aged 50 years who received his first transplant from a living related kidney donor. To our knowledge, this case is the first reported of belatacept use in an HIV-positive renal transplant recipient.
基于贝拉西普的免疫抑制方案在人类免疫缺陷病毒（HIV）阳性肾移植受者中的益处包括避免钙调神经磷酸酶抑制剂与高效抗逆转录病毒药物之间的药物相互作用，以及降低非免疫毒性（如移植后新发糖尿病、高脂血症和高血压）的发生可能性或严重程度。我们报告了一例成功案例，一名50岁的HIV阳性黑人男性在接受活体亲属肾供者的首次移植后超过18个月开始使用贝拉西普。据我们所知，该病例是首次报道在HIV阳性肾移植受者中使用贝拉西普。
